WallStreetZenWallStreetZen

NASDAQ: WINT
Windtree Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for WINT

Based on 1 analyst offering 12 month price targets for Windtree Therapeutics Inc.
Min Forecast
$18.00+230.28%
Avg Forecast
$18.00+230.28%
Max Forecast
$18.00+230.28%

Should I buy or sell WINT stock?

Based on 1 analyst offering ratings for Windtree Therapeutics Inc.
Hold
Strong Buy
0 analysts 0%
Buy
0 analysts 0%
Hold
1 analysts 100%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their WINT stock forecasts and price targets.

WINT stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-01-03

1 of 1

Forecast return on equity

Is WINT forecast to generate an efficient return?
Company
N/A
Industry
-62.55%
Market
20.01%

Forecast return on assets

Is WINT forecast to generate an efficient return on assets?
Company
N/A
Industry
6.28%

WINT revenue forecast

What is WINT's revenue in the next 1 years based on estimates from 1 analyst?
Avg 1 year Forecast
$87.3M

WINT vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
WINT$5.45$18.00+230.28%Hold
ONCO$0.12N/AN/A
RNAZ$0.46$3.00+553.59%Buy
SXTP$0.25N/AN/A
BPTS$0.25N/AN/A
View Top Biotech Stocks

Windtree Therapeutics Stock Forecast FAQ

Is Windtree Therapeutics Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: WINT) stock is to Hold WINT stock.

Out of 1 analyst, 0 (0%) are recommending WINT as a Strong Buy, 0 (0%) are recommending WINT as a Buy, 1 (100%) are recommending WINT as a Hold, 0 (0%) are recommending WINT as a Sell, and 0 (0%) are recommending WINT as a Strong Sell.

If you're new to stock investing, here's how to buy Windtree Therapeutics stock.

What is WINT's revenue growth forecast for 2030-2030?

(NASDAQ: WINT) Windtree Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 59.52%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.23%.

Windtree Therapeutics's revenue in 2024 is $0.

In 2030, WINT is forecast to generate $44,538,627 in revenue, with the lowest revenue forecast at $44,538,627 and the highest revenue forecast at $44,538,627.

What is WINT's forecast return on assets (ROA) for 2024-2026?

(NASDAQ: WINT) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 6.28%.

What is WINT's Price Target?

According to 1 Wall Street analyst that have issued a 1 year WINT price target, the average WINT price target is $18.00, with the highest WINT stock price forecast at $18.00 and the lowest WINT stock price forecast at $18.00.

The Wall Street analyst predicted that Windtree Therapeutics's share price could reach $18.00 by Jan 3, 2025. The average Windtree Therapeutics stock price prediction forecasts a potential upside of 230.28% from the current WINT share price of $5.45.

What is WINT's forecast return on equity (ROE) for 2024-2026?

(NASDAQ: WINT) forecast ROE is N/A, which is considered weak.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.